Advertisement

Small molecules for modulating the localisation of the water channel aquaporin-2—disease relevance and perspectives for targeting local cAMP signalling

  • Sandrine Baltzer
  • Enno KlussmannEmail author
Review

Abstract

The tight spatial and temporal organisation of cyclic adenosine monophosphate (cAMP) signalling plays a key role in arginine-vasopressin (AVP)-mediated water reabsorption in renal collecting duct principal cells and in a plethora of other processes such as in the control of cardiac myocyte contractility. This review critically discusses in vitro- and cell-based screening strategies for the identification of small molecules that interfere with AVP/cAMP signalling in renal principal cells; it features phenotypic screening and approaches for targeting protein–protein interactions of A-kinase anchoring proteins (AKAPs), which organise local cAMP signalling hubs. The discovery of novel chemical entities for the modulation of local cAMP will not only provide tools for elucidating molecular mechanisms underlying cAMP signalling. Novel chemical entities can also serve as starting points for the development of novel drugs for the treatment of human diseases. Examples illustrate how screening for small molecules can pave the way to novel approaches for the treatment of certain forms of diabetes insipidus, a disease caused by defects in AVP-mediated water reabsorption.

Keywords

Aquaporin-2 AVP A-kinase anchoring protein AKAP cAMP signalling Protein kinase A PKA Screening Small molecule Protein–protein interaction PDE 

Notes

Author contribution statement

SB and EK analysed the data and wrote the manuscript. Both authors read and approved the manuscript.

Funding information

This work was supported by grants from the Bundesministerium für Bildung und Forschung (BMBF; 16GW0179K), the Deutsche Forschungsgemeinschaft (German Research Foundation, DFG KL1415/7-1 and 394046635 – SFB 1365), the German Centre for Cardiovascular Research (DZHK) partner site Berlin (81X2100146) and the German Israeli Foundation (GIF, I-1452-203/13-2018).

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. Abdul Azeez KR, Knapp S, Fernandes JM, Klussmann E, Elkins JM (2014) The crystal structure of the RhoA-AKAP-Lbc DH-PH domain complex. Biochem J 464:231–239CrossRefPubMedPubMedCentralGoogle Scholar
  2. Alto NM, Soderling SH, Hoshi N, Langeberg LK, Fayos R, Jennings PA, Scott JD (2003) Bioinformatic design of A-kinase anchoring protein-in silico: a potent and selective peptide antagonist of type II protein kinase A anchoring. Proc Natl Acad Sci U S A 100:4445–4450CrossRefPubMedPubMedCentralGoogle Scholar
  3. Ando F, Mori S, Yui N, Morimoto T, Nomura N, Sohara E, Rai T, Sasaki S, Kondo Y, Kagechika H, Uchida S (2018) AKAPs-PKA disruptors increase AQP2 activity independently of vasopressin in a model of nephrogenic diabetes insipidus. Nat Commun 9:1411CrossRefPubMedPubMedCentralGoogle Scholar
  4. Anselmo AC, Gokarn Y, Mitragotri S (2018) Non-invasive delivery strategies for biologics. Nat Rev Drug DiscovGoogle Scholar
  5. Arkin MR, Tang Y, Wells JA (2014) Small-molecule inhibitors of protein-protein interactions: progressing toward the reality. Chem Biol 21:1102–1114CrossRefPubMedPubMedCentralGoogle Scholar
  6. Ashkenazi A, Fairbrother WJ, Leverson JD, Souers AJ (2017) From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors. Nat Rev Drug Discov 16:273–284CrossRefPubMedGoogle Scholar
  7. Aye TT, Soni S, van Veen TA, van der Heyden MA, Cappadona S, Varro A, de Weger RA, de Jonge N, Vos MA, Heck AJ, Scholten A (2012) Reorganized PKA-AKAP associations in the failing human heart. J Mol Cell Cardiol 52:511–518CrossRefPubMedGoogle Scholar
  8. Azzarito V, Long K, Murphy NS, Wilson AJ (2013) Inhibition of α-helix-mediated protein-protein interactions using designed molecules. Nat Chem 5:161–173CrossRefPubMedGoogle Scholar
  9. Banky P, Roy M, Newlon MG, Morikis D, Haste NM, Taylor SS, Jennings PA (2003) Related protein-protein interaction modules present drastically different surface topographies despite a conserved helical platform. J Mol Biol 330:1117–1129CrossRefPubMedGoogle Scholar
  10. Bastug-Ozel Z, Wright PT, Kraft AE, Pavlovic D, Howie J, Froese A, Fuller W, Gorelik J, Shattock MJ, Nikolaev VO (2019) Heart failure leads to altered beta2-adrenoceptor/cyclic adenosine monophosphate dynamics in the sarcolemmal phospholemman/Na,K ATPase microdomain. Cardiovasc Res 115: 546-555Google Scholar
  11. Bendzunas NG, Dorfler S, Autenrieth K, Bertinetti D, Machal EMF, Kennedy EJ, Herberg FW (2018) Investigating PKA-RII specificity using analogs of the PKA:AKAP peptide inhibitor STAD-2. Bioorg Med Chem 26:1174–1178CrossRefPubMedPubMedCentralGoogle Scholar
  12. Bichet DG (2008) Vasopressin receptor mutations in nephrogenic diabetes insipidus. Semin Nephrol 28:245–251CrossRefPubMedGoogle Scholar
  13. Bockenhauer D, Bichet DG (2017) Nephrogenic diabetes insipidus. Curr Opin Pediatr 29:199–205CrossRefPubMedGoogle Scholar
  14. Bogan AA, Thorn KS (1998) Anatomy of hot spots in protein interfaces. J Mol Biol 280:1–9CrossRefPubMedPubMedCentralGoogle Scholar
  15. Bogum J, Faust D, Zuhlke K, Eichhorst J, Moutty MC, Furkert J, Eldahshan A, Neuenschwander M, von Kries JP, Wiesner B, Trimpert C, Deen PM, Valenti G, Rosenthal W, Klussmann E (2013) Small-molecule screening identifies modulators of aquaporin-2 trafficking. J Am Soc Nephrol 24:744–758CrossRefPubMedPubMedCentralGoogle Scholar
  16. Bouley R, Breton S, Sun T, McLaughlin M, Nsumu NN, Lin HY, Ausiello DA, Brown D (2000) Nitric oxide and atrial natriuretic factor stimulate cGMP-dependent membrane insertion of aquaporin 2 in renal epithelial cells. J Clin Invest 106:1115–1126CrossRefPubMedPubMedCentralGoogle Scholar
  17. Bradford D, Raghuram V, Wilson JL, Chou CL, Hoffert JD, Knepper MA, Pisitkun T (2014) Use of LC-MS/MS and Bayes’ theorem to identify protein kinases that phosphorylate aquaporin-2 at Ser256. Am J Phys Cell Phys 307:C123–C139CrossRefGoogle Scholar
  18. Brand T, Schindler R (2017) New kids on the block: the Popeye domain containing (POPDC) protein family acting as a novel class of cAMP effector proteins in striated muscle. Cell Signal 40:156–165CrossRefPubMedPubMedCentralGoogle Scholar
  19. Breckenridge A, Jacob R (2019) Overcoming the legal and regulatory barriers to drug repurposing. Nat Rev Drug Discov 18:1–2CrossRefPubMedGoogle Scholar
  20. Brown D, Breton S, Ausiello DA, Marshansky V (2009) Sensing, signaling and sorting events in kidney epithelial cell physiology. Traffic 10:275–284CrossRefPubMedPubMedCentralGoogle Scholar
  21. Burdyga A, Surdo NC, Monterisi S, Di Benedetto G, Grisan F, Penna E, Pellegrini L, Bortolozzi M, Swietach P, Pozzan T, Lefkimmiatis K (2018) Phosphatases control PKA-dependent functional microdomains at the outer mitochondrial membrane. Proc Natl Acad Sci U S A 115:E6497–E6506CrossRefPubMedPubMedCentralGoogle Scholar
  22. Carr DW, Stofko-Hahn RE, Fraser ID, Bishop SM, Acott TS, Brennan RG, Scott JD (1991) Interaction of the regulatory subunit (RII) of cAMP-dependent protein kinase with RII-anchoring proteins occurs through an amphipathic helix binding motif. J Biol Chem 266:14188–14192PubMedGoogle Scholar
  23. Carr DW, Hausken ZE, Fraser ID, Stofko-Hahn RE, Scott JD (1992) Association of the type II cAMP-dependent protein kinase with a human thyroid RII-anchoring protein. Cloning and characterization of the RII-binding domain. J Biol Chem 267:13376–13382PubMedGoogle Scholar
  24. Cheung PW, Nomura N, Nair AV, Pathomthongtaweechai N, Ueberdiek L, Lu HA, Brown D, Bouley R (2016) EGF receptor inhibition by erlotinib increases aquaporin 2-mediated renal water reabsorption. J Am Soc Nephrol 27:3105–3116CrossRefPubMedPubMedCentralGoogle Scholar
  25. Christian F, Szaszak M, Friedl S, Drewianka S, Lorenz D, Goncalves A, Furkert J, Vargas C, Schmieder P, Götz F, Zühlke K, Moutty M, Gottert H, Joshi M, Reif B, Haase H, Morano I, Grossmann S, Klukovits A, Verli J, Gaspar R, Noack C, Bergmann M, Kass R, Hampel K, Kashin D, Genieser HG, Herberg FW, Willoughby D, Cooper DM, Baillie GS, Houslay MD, von Kries JP, Zimmermann B, Rosenthal W, Klussmann E (2011) Small molecule AKAP-protein kinase A (PKA) interaction disruptors that activate PKA interfere with compartmentalized cAMP signaling in cardiac myocytes. J Biol Chem 286:9079–9096CrossRefGoogle Scholar
  26. Coffey AK, O’Sullivan DJ, Homma S, Dousa TP, Valtin H (1991) Induction of intramembranous particle clusters in mice with nephrogenic diabetes insipidus. Am J Phys 261:F640–F646Google Scholar
  27. Conti M, Beavo J (2007) Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling. Annu Rev Biochem 76:481–511CrossRefPubMedGoogle Scholar
  28. Craik DJ, Fairlie DP, Liras S, Price D (2013) The future of peptide-based drugs. Chem Biol Drug Des 81:136–147CrossRefPubMedGoogle Scholar
  29. Cummings CG, Hamilton AD (2010) Disrupting protein–protein interactions with non-peptidic, small molecule α-helix mimetics. Curr Opin Chem Biol 14:341–346CrossRefPubMedGoogle Scholar
  30. Davis JM, Tsou LK, Hamilton AD (2007) Synthetic non-peptide mimetics of alpha-helices. Chem Soc Rev 36:326–334CrossRefPubMedGoogle Scholar
  31. Dayal D, Verma Attri S, Kumar Bhalla A, Kumar R (2015) Response to low dose indomethacin in two children with nephrogenic diabetes insipidus. Pediatr Endocrinol Diabetes Metab 20:178–181CrossRefPubMedGoogle Scholar
  32. Dema A, Perets E, Schulz MS, Deak VA, Klussmann E (2015) Pharmacological targeting of AKAP-directed compartmentalized cAMP signalling. Cell Signal 27:2474–2487CrossRefPubMedGoogle Scholar
  33. Diviani D, Soderling J, Scott JD (2001) AKAP-Lbc anchors protein kinase A and nucleates Galpha 12-selective Rho-mediated stress fiber formation. J Biol Chem 276:44247–44257CrossRefPubMedGoogle Scholar
  34. Diviani D, Raimondi F, Del Vescovo CD, Dreyer E, Reggi E, Osman H, Ruggieri L, Gonano C, Cavin S, Box CL, Lenoir M, Overduin M, Bellucci L, Seeber M, Fanelli F (2016) Small-molecule protein-protein interaction inhibitor of oncogenic Rho signaling. Cell Chem Biol 23:1135–1146CrossRefPubMedGoogle Scholar
  35. Eccles RL, Czajkowski MT, Barth C, Muller PM, McShane E, Grunwald S, Beaudette P, Mecklenburg N, Volkmer R, Zuhlke K, Dittmar G, Selbach M, Hammes A, Daumke O, Klussmann E, Urbe S, Rocks O (2016) Bimodal antagonism of PKA signalling by ARHGAP36. Nat Commun 7:12963CrossRefPubMedPubMedCentralGoogle Scholar
  36. Efe O, Klein JD, LaRocque LM, Ren H, Sands JM (2016) Metformin improves urine concentration in rodents with nephrogenic diabetes insipidus. JCI Insight 1Google Scholar
  37. Erickson KF, Chertow GM, Goldhaber-Fiebert JD (2013) Cost-effectiveness of tolvaptan in autosomal dominant polycystic kidney disease. Ann Intern Med 159:382–389CrossRefPubMedPubMedCentralGoogle Scholar
  38. Faust D, Geelhaar A, Eisermann B, Eichhorst J, Wiesner B, Rosenthal W, Klussmann E, Klussman E (2013) Culturing primary rat inner medullary collecting duct cells. J Vis ExpGoogle Scholar
  39. Fenton RA, Moeller HB, Hoffert JD, Yu MJ, Nielsen S, Knepper MA (2008) Acute regulation of aquaporin-2 phosphorylation at Ser-264 by vasopressin. Proc Natl Acad Sci U S A 105:3134–3139CrossRefPubMedPubMedCentralGoogle Scholar
  40. Fink MA, Zakhary DR, Mackey JA, Desnoyer RW, Apperson-Hansen C, Damron DS, Bond M (2001) AKAP-mediated targeting of protein kinase A regulates contractility in cardiac myocytes. Circ Res 88:291–297CrossRefPubMedGoogle Scholar
  41. Francis SH, Blount MA, Corbin JD (2011) Mammalian cyclic nucleotide phosphodiesterases: molecular mechanisms and physiological functions. Physiol Rev 91:651–690CrossRefPubMedGoogle Scholar
  42. Fraser ID, Tavalin SJ, Lester LB, Langeberg LK, Westphal AM, Dean RA, Marrion NV, Scott JD (1998) A novel lipid-anchored A-kinase anchoring protein facilitates cAMP-responsive membrane events. EMBO J 17:2261–2272CrossRefPubMedPubMedCentralGoogle Scholar
  43. Fujiwara TM, Bichet DG (2005) Molecular biology of hereditary diabetes insipidus. J Am Soc Nephrol 16:2836–2846CrossRefPubMedGoogle Scholar
  44. Fushimi K, Sasaki S, Marumo F (1997) Phosphorylation of serine 256 is required for cAMP-dependent regulatory exocytosis of the aquaporin-2 water channel. J Biol Chem 272:14800–14804CrossRefPubMedGoogle Scholar
  45. Gentilucci L, De Marco R, Cerisoli L (2010) Chemical modifications designed to improve peptide stability: incorporation of non-natural amino acids, pseudo-peptide bonds, and cyclization. Curr Pharm Des 16:3185–3203CrossRefPubMedGoogle Scholar
  46. Gilotra NA, Russell SD (2014) Arginine vasopressin as a target in the treatment of acute heart failure. World J Cardiol 6:1252–1261CrossRefPubMedPubMedCentralGoogle Scholar
  47. Götz F, Roske Y, Schulz MS, Autenrieth K, Bertinetti D, Faelber K, Zuhlke K, Kreuchwig A, Kennedy EJ, Krause G, Daumke O, Herberg FW, Heinemann U, Klussmann E (2016) AKAP18:PKA-RIIalpha structure reveals crucial anchor points for recognition of regulatory subunits of PKA. Biochem J 473:1881–1894CrossRefPubMedPubMedCentralGoogle Scholar
  48. Guo W, Wisniewski JA, Ji H (2014) Hot spot-based design of small-molecule inhibitors for protein-protein interactions. Bioorg Med Chem Lett 24:2546–2554CrossRefPubMedGoogle Scholar
  49. Halls ML, Cooper DM (2017) Adenylyl cyclase signalling complexes—pharmacological challenges and opportunities. Pharmacol Ther 172:171–180CrossRefPubMedGoogle Scholar
  50. Henn V, Edemir B, Stefan E, Wiesner B, Lorenz D, Theilig F, Schmitt R, Vossebein L, Tamma G, Beyermann M, Krause E, Herberg FW, Valenti G, Bachmann S, Rosenthal W, Klussmann E (2004) Identification of a novel A-kinase anchoring protein 18 isoform and evidence for its role in the vasopressin-induced aquaporin-2 shuttle in renal principal cells. J Biol Chem 279:26654–26665CrossRefPubMedGoogle Scholar
  51. Henn V, Stefan E, Baillie GS, Houslay MD, Rosenthal W, Klussmann E (2005) Compartmentalized cAMP signalling regulates vasopressin-mediated water reabsorption by controlling aquaporin-2. Biochem Soc Trans 33:1316–1318CrossRefPubMedGoogle Scholar
  52. Hoffert JD, Fenton RA, Moeller HB, Simons B, Tchapyjnikov D, McDill BW, Yu MJ, Pisitkun T, Chen F, Knepper MA (2008) Vasopressin-stimulated increase in phosphorylation at Ser269 potentiates plasma membrane retention of aquaporin-2. J Biol Chem 283:24617–24627CrossRefPubMedPubMedCentralGoogle Scholar
  53. Huggins DJ, Venkitaraman AR, Spring DR (2011) Rational methods for the selection of diverse screening compounds. ACS Chem Biol 6:208–217CrossRefPubMedPubMedCentralGoogle Scholar
  54. Hundsrucker C, Klussmann E (2008) Direct AKAP-mediated protein-protein interactions as potential drug targets. Handb Exp Pharmacol:483–503Google Scholar
  55. Hundsrucker C, Krause G, Beyermann M, Prinz A, Zimmermann B, Diekmann O, Lorenz D, Stefan E, Nedvetsky P, Dathe M, Christian F, McSorley T, Krause E, McConnachie G, Herberg FW, Scott JD, Rosenthal W, Klussmann E (2006a) High-affinity AKAP7delta-protein kinase A interaction yields novel protein kinase A-anchoring disruptor peptides. Biochem J 396:297–306CrossRefPubMedPubMedCentralGoogle Scholar
  56. Hundsrucker C, Rosenthal W, Klussmann E (2006b) Peptides for disruption of PKA anchoring. Biochem Soc Trans 34:472–473CrossRefPubMedGoogle Scholar
  57. Inglese J, Johnson RL, Simeonov A, Xia M, Zheng W, Austin CP, Auld DS (2007) High-throughput screening assays for the identification of chemical probes. Nat Chem Biol 3:466–479CrossRefPubMedGoogle Scholar
  58. Iolascon A, Aglio V, Tamma G, D’Apolito M, Addabbo F, Procino G, Simonetti MC, Montini G, Gesualdo L, Debler EW, Svelto M, Valenti G (2007) Characterization of two novel missense mutations in the AQP2 gene causing nephrogenic diabetes insipidus. Nephron Physiol 105:p33–p41CrossRefPubMedGoogle Scholar
  59. Isobe K, Jung HJ, Yang CR, Claxton J, Sandoval P, Burg MB, Raghuram V, Knepper MA (2017) Systems-level identification of PKA-dependent signaling in epithelial cells. Proc Natl Acad Sci U S A 114:E8875–E8884CrossRefPubMedPubMedCentralGoogle Scholar
  60. Kamsteeg EJ, Hendriks G, Boone M, Konings IB, Oorschot V, van der Sluijs P, Klumperman J, Deen PM (2006) Short-chain ubiquitination mediates the regulated endocytosis of the aquaporin-2 water channel. Proc Natl Acad Sci U S A 103:18344–18349CrossRefPubMedPubMedCentralGoogle Scholar
  61. Khan A, Munir M, Aiman S, Wadood A, Khan AU (2017) The in silico identification of small molecules for protein-protein interaction inhibition in AKAP-Lbc-RhoA signaling complex. Comput Biol Chem 67:84–91CrossRefPubMedGoogle Scholar
  62. Kinderman FS, Kim C, von Daake S, Ma Y, Pham BQ, Spraggon G, Xuong NH, Jennings PA, Taylor SS (2006) A novel and dynamic mechanism for AKAP binding to RII isoforms of cAMP-dependent protein kinase. Mol Cell 24:397–408CrossRefPubMedPubMedCentralGoogle Scholar
  63. Klussmann E, Rosenthal W (2001) Role and identification of protein kinase A anchoring proteins in vasopressin-mediated aquaporin-2 translocation. Kidney Int 60:446–449CrossRefPubMedGoogle Scholar
  64. Klussmann E, Maric K, Wiesner B, Beyermann M, Rosenthal W (1999) Protein kinase A anchoring proteins are required for vasopressin-mediated translocation of aquaporin-2 into cell membranes of renal principal cells. J Biol Chem 274:4934–4938CrossRefPubMedGoogle Scholar
  65. Klussmann E, Maric K, Rosenthal W (2000) The mechanisms of aquaporin control in the renal collecting duct. Rev Physiol Biochem Pharmacol 141:33–95CrossRefPubMedGoogle Scholar
  66. Klussmann E, Edemir B, Pepperle B, Tamma G, Henn V, Klauschenz E, Hundsrucker C, Maric K, Rosenthal W (2001a) Ht31: the first protein kinase A anchoring protein to integrate protein kinase A and Rho signaling. FEBS Lett 507:264–268CrossRefPubMedGoogle Scholar
  67. Klussmann E, Tamma G, Lorenz D, Wiesner B, Maric K, Hofmann F, Aktories K, Valenti G, Rosenthal W (2001b) An inhibitory role of Rho in the vasopressin-mediated translocation of aquaporin-2 into cell membranes of renal principal cells. J Biol Chem 276:20451–20457CrossRefPubMedGoogle Scholar
  68. Kopperud R, Christensen AE, Kjarland E, Viste K, Kleivdal H, Doskeland SO (2002) Formation of inactive cAMP-saturated holoenzyme of cAMP-dependent protein kinase under physiological conditions. J Biol Chem 277:13443–13448CrossRefPubMedGoogle Scholar
  69. Kuenemann MA, Sperandio O, Labbe CM, Lagorce D, Miteva MA, Villoutreix BO (2015) In silico design of low molecular weight protein-protein interaction inhibitors: overall concept and recent advances. Prog Biophys Mol Biol 119:20–32CrossRefPubMedGoogle Scholar
  70. Langeberg LK, Scott JD (2015) Signalling scaffolds and local organization of cellular behaviour. Nat Rev Mol Cell BiolGoogle Scholar
  71. Laraia L, McKenzie G, Spring DR, Venkitaraman AR, Huggins DJ (2015) Overcoming chemical, biological, and computational challenges in the development of inhibitors targeting protein-protein interactions. Chem Biol 22:689–703CrossRefPubMedPubMedCentralGoogle Scholar
  72. Lee YJ, Lee JE, Choi HJ, Lim JS, Jung HJ, Baek MC, Frokiaer J, Nielsen S, Kwon TH (2011) E3 ubiquitin-protein ligases in rat kidney collecting duct: response to vasopressin stimulation and withdrawal. Am J Physiol Ren Physiol 301:F883–F896CrossRefGoogle Scholar
  73. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ (2001) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 46:3–26CrossRefGoogle Scholar
  74. Lisurek M, Rupp B, Wichard J, Neuenschwander M, von Kries JP, Frank R, Rademann J, Kuhne R (2010) Design of chemical libraries with potentially bioactive molecules applying a maximum common substructure concept. Mol Divers 14:401–408CrossRefPubMedGoogle Scholar
  75. Liu R, Li X, Lam KS (2017) Combinatorial chemistry in drug discovery. Curr Opin Chem Biol 38:117–126CrossRefPubMedPubMedCentralGoogle Scholar
  76. Lygren B, Carlson CR, Santamaria K, Lissandron V, McSorley T, Litzenberg J, Lorenz D, Wiesner B, Rosenthal W, Zaccolo M, Tasken K, Klussmann E (2007) AKAP complex regulates Ca2+ re-uptake into heart sarcoplasmic reticulum. EMBO Rep 8:1061–1067CrossRefPubMedPubMedCentralGoogle Scholar
  77. Lyu J, Wang S, Balius TE, Singh I, Levit A, Moroz YS, O'Meara MJ, Che T, Algaa E, Tolmachova K, Tolmachev AA, Shoichet BK, Roth BL, Irwin JJ (2019) Ultra-large library docking for discovering new chemotypes. Nature 566:224–229CrossRefPubMedGoogle Scholar
  78. McConnell BK, Popovic Z, Mal N, Lee K, Bautista J, Forudi F, Schwartzman R, Jin JP, Penn M, Bond M (2009) Disruption of protein kinase A interaction with A-kinase-anchoring proteins in the heart in vivo: effects on cardiac contractility, protein kinase A phosphorylation, and troponin I proteolysis. J Biol Chem 284:1583–1592CrossRefPubMedPubMedCentralGoogle Scholar
  79. McSorley T, Stefan E, Henn V, Wiesner B, Baillie GS, Houslay MD, Rosenthal W, Klussmann E (2006) Spatial organisation of AKAP18 and PDE4 isoforms in renal collecting duct principal cells. Eur J Cell Biol 85:673–678CrossRefPubMedGoogle Scholar
  80. Milano S, Carmosino M, Gerbino A, Svelto M, Procino G (2017) Hereditary nephrogenic diabetes insipidus: pathophysiology and possible treatment. an update. Int J Mol Sci:18Google Scholar
  81. Miranda ER, Nam EA, Kuspa A, Shaulsky G (2015) The ABC transporter, AbcB3, mediates cAMP export in D. discoideum development. Dev Biol 397:203–211CrossRefPubMedGoogle Scholar
  82. Moeller HB, Praetorius J, Rutzler MR, Fenton RA (2010) Phosphorylation of aquaporin-2 regulates its endocytosis and protein-protein interactions. Proc Natl Acad Sci U S A 107:424–429CrossRefPubMedGoogle Scholar
  83. Moeller HB, Aroankins TS, Slengerik-Hansen J, Pisitkun T, Fenton RA (2014) Phosphorylation and ubiquitylation are opposing processes that regulate endocytosis of the water channel aquaporin-2. J Cell Sci 127:3174–3183CrossRefPubMedGoogle Scholar
  84. Murali SK, Aroankins TS, Moeller HB, Fenton RA (2019) The deubiquitylase USP4 interacts with the water channel AQP2 to modulate its apical membrane accumulation and cellular abundance. Cells 8Google Scholar
  85. Nedvetsky PI, Stefan E, Frische S, Santamaria K, Wiesner B, Valenti G, Hammer JA 3rd, Nielsen S, Goldenring JR, Rosenthal W, Klussmann E (2007) A role of myosin Vb and Rab11-FIP2 in the aquaporin-2 shuttle. Traffic 8:110–123CrossRefPubMedGoogle Scholar
  86. Nedvetsky PI, Tamma G, Beulshausen S, Valenti G, Rosenthal W, Klussmann E (2009) Regulation of aquaporin-2 trafficking. Handb Exp Pharmacol:133–157Google Scholar
  87. Nedvetsky PI, Tabor V, Tamma G, Beulshausen S, Skroblin P, Kirschner A, Mutig K, Boltzen M, Petrucci O, Vossenkamper A, Wiesner B, Bachmann S, Rosenthal W, Klussmann E (2010) Reciprocal regulation of aquaporin-2 abundance and degradation by protein kinase A and p38-MAP kinase. J Am Soc Nephrol 21:1645–1656CrossRefPubMedPubMedCentralGoogle Scholar
  88. Newlon MG, Roy M, Morikis D, Hausken ZE, Coghlan V, Scott JD, Jennings PA (1999) The molecular basis for protein kinase A anchoring revealed by solution NMR. Nat Struct Biol 6:222–227CrossRefPubMedGoogle Scholar
  89. Nishimoto G, Zelenina M, Li D, Yasui M, Aperia A, Nielsen S, Nairn AC (1999) Arginine vasopressin stimulates phosphorylation of aquaporin-2 in rat renal tissue. Am J Phys 276:F254–F259Google Scholar
  90. Noda Y, Sohara E, Ohta E, Sasaki S (2010) Aquaporins in kidney pathophysiology. Nat Rev Nephrol 6:168–178CrossRefPubMedGoogle Scholar
  91. Okutsu R, Rai T, Kikuchi A, Ohno M, Uchida K, Sasaki S, Uchida S (2008) AKAP220 colocalizes with AQP2 in the inner medullary collecting ducts. Kidney Int 74:1429–1433CrossRefPubMedGoogle Scholar
  92. Olesen ET, Fenton RA (2017) Aquaporin-2 membrane targeting: still a conundrum. Am J Physiol Ren Physiol 312:F744–F747CrossRefGoogle Scholar
  93. Omar F, Findlay JE, Carfray G, Allcock RW, Jiang Z, Moore C, Muir AL, Lannoy M, Fertig BA, Mai D, Day JP, Bolger G, Baillie GS, Schwiebert E, Klussmann E, Pyne NJ, Ong ACM, Bowers K, Adam JM, Adams DR, Houslay MD, Henderson DJP (2019) Small-molecule allosteric activators of PDE4 long form cyclic AMP phosphodiesterases. Proc Natl Acad Sci U S AGoogle Scholar
  94. Ong AC, Devuyst O, Knebelmann B, Walz G, Diseases E-EWGIK (2015) Autosomal dominant polycystic kidney disease: the changing face of clinical management. Lancet 385:1993–2002CrossRefPubMedGoogle Scholar
  95. Petta I, Lievens S, Libert C, Tavernier J, De Bosscher K (2016) Modulation of protein-protein interactions for the development of novel therapeutics. Mol Ther 24:707–718CrossRefPubMedPubMedCentralGoogle Scholar
  96. Pushpakom S, Iorio F, Eyers PA, Escott KJ, Hopper S, Wells A, Doig A, Guilliams T, Latimer J, McNamee C, Norris A, Sanseau P, Cavalla D, Pirmohamed M (2018) Drug repurposing: progress, challenges and recommendations. Nat Rev Drug DiscovGoogle Scholar
  97. Qureshi S, Galiveeti S, Bichet DG, Roth J (2014) Diabetes insipidus: celebrating a century of vasopressin therapy. Endocrinology 155:4605–4621CrossRefPubMedGoogle Scholar
  98. Ranieri M, Di Mise A, Tamma G, Valenti G (2019) Vasopressin-aquaporin-2 pathway: recent advances in understanding water balance disorders. F1000Res 8Google Scholar
  99. Robichaux WG 3rd, Cheng X (2018) Intracellular cAMP sensor EPAC: physiology, pathophysiology, and therapeutics development. Physiol Rev 98:919–1053CrossRefPubMedPubMedCentralGoogle Scholar
  100. Sarma GN, Kinderman FS, Kim C, von Daake S, Chen L, Wang BC, Taylor SS (2010) Structure of D-AKAP2:PKA RI complex: insights into AKAP specificity and selectivity. Structure 18:155–166CrossRefPubMedPubMedCentralGoogle Scholar
  101. Schächterle C, Christian F, Fernandes JM, Klussmann E (2015) Screening for small molecule disruptors of AKAP-PKA interactions. Methods Mol Biol 1294:151–166CrossRefPubMedGoogle Scholar
  102. Schäfer G, Milic J, Eldahshan A, Götz F, Zuhlke K, Schillinger C, Kreuchwig A, Elkins JM, Abdul Azeez KR, Oder A, Moutty MC, Masada N, Beerbaum M, Schlegel B, Niquet S, Schmieder P, Krause G, von Kries JP, Cooper DM, Knapp S, Rademann J, Rosenthal W, Klussmann E (2013) Highly functionalized terpyridines as competitive inhibitors of AKAP-PKA interactions. Angew Chem Int Ed Eng 52:12187–12191CrossRefGoogle Scholar
  103. Schobesberger S, Wright P, Tokar S, Bhargava A, Mansfield C, Glukhov AV, Poulet C, Buzuk A, Monszpart A, Sikkel M, Harding SE, Nikolaev VO, Lyon AR, Gorelik J (2017) T-tubule remodelling disturbs localized beta2-adrenergic signalling in rat ventricular myocytes during the progression of heart failure. Cardiovasc Res 113:770–782CrossRefPubMedPubMedCentralGoogle Scholar
  104. Schrade K, Troger J, Eldahshan A, Zuhlke K, Abdul Azeez KR, Elkins JM, Neuenschwander M, Oder A, Elkewedi M, Jaksch S, Andrae K, Li J, Fernandes J, Muller PM, Grunwald S, Marino SF, Vukicevic T, Eichhorst J, Wiesner B, Weber M, Kapiloff M, Rocks O, Daumke O, Wieland T, Knapp S, von Kries JP, Klussmann E (2018) An AKAP-Lbc-RhoA interaction inhibitor promotes the translocation of aquaporin-2 to the plasma membrane of renal collecting duct principal cells. PLoS One 13:e0191423CrossRefPubMedPubMedCentralGoogle Scholar
  105. Scott JD, Dessauer CW, Tasken K (2013) Creating order from chaos: cellular regulation by kinase anchoring. Annu Rev Pharmacol Toxicol 53:187–210CrossRefPubMedGoogle Scholar
  106. Scott DE, Bayly AR, Abell C, Skidmore J (2016) Small molecules, big targets: drug discovery faces the protein-protein interaction challenge. Nat Rev Drug Discov 15:533–550CrossRefPubMedGoogle Scholar
  107. Sheng C, Dong G, Miao Z, Zhang W, Wang W (2015) State-of-the-art strategies for targeting protein-protein interactions by small-molecule inhibitors. Chem Soc Rev 44:8238–8259CrossRefPubMedGoogle Scholar
  108. Skroblin P, Grossmann S, Schäfer G, Rosenthal W, Klussmann E (2010) Mechanisms of protein kinase a anchoring. Int Rev Cell Mol Biol 283:235–330CrossRefPubMedGoogle Scholar
  109. Smith FD, Esseltine JL, Nygren PJ, Veesler D, Byrne DP, Vonderach M, Strashnov I, Eyers CE, Eyers PA, Langeberg LK, Scott JD (2017) Local protein kinase A action proceeds through intact holoenzymes. Science 356:1288–1293CrossRefPubMedPubMedCentralGoogle Scholar
  110. Smith FD, Omar MH, Nygren PJ, Soughayer J, Hoshi N, Lau HT, Snyder CG, Branon TC, Ghosh D, Langeberg LK, Ting AY, Santana LF, Ong SE, Navedo MF, Scott JD (2018) Single nucleotide polymorphisms alter kinase anchoring and the subcellular targeting of A-kinase anchoring proteins. Proc Natl Acad Sci U S A 115:E11465–E11474CrossRefPubMedPubMedCentralGoogle Scholar
  111. Sørensen MG, Henriksen K, Neutzsky-Wulff AV, Dziegiel MH, Karsdal MA (2007) Diphyllin, a novel and naturally potent V-ATPase inhibitor, abrogates acidification of the osteoclastic resorption lacunae and bone resorption. J Bone Miner Res 22:1640–1648CrossRefPubMedGoogle Scholar
  112. Souers AJ, Leverson JD, Boghaert ER, Ackler SL, Catron ND, Chen J, Dayton BD, Ding H, Enschede SH, Fairbrother WJ, Huang DC, Hymowitz SG, Jin S, Khaw SL, Kovar PJ, Lam LT, Lee J, Maecker HL, Marsh KC, Mason KD, Mitten MJ, Nimmer PM, Oleksijew A, Park CH, Park CM, Phillips DC, Roberts AW, Sampath D, Seymour JF, Smith ML, Sullivan GM, Tahir SK, Tse C, Wendt MD, Xiao Y, Xue JC, Zhang H, Humerickhouse RA, Rosenberg SH, Elmore SW (2013) ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med 19:202–208CrossRefGoogle Scholar
  113. Stefan E, Wiesner B, Baillie GS, Mollajew R, Henn V, Lorenz D, Furkert J, Santamaria K, Nedvetsky P, Hundsrucker C, Beyermann M, Krause E, Pohl P, Gall I, MacIntyre AN, Bachmann S, Houslay MD, Rosenthal W, Klussmann E (2007) Compartmentalization of cAMP-dependent signaling by phosphodiesterase-4D is involved in the regulation of vasopressin-mediated water reabsorption in renal principal cells. J Am Soc Nephrol 18:199–212CrossRefPubMedGoogle Scholar
  114. Szaszák M, Christian F, Rosenthal W, Klussmann E (2008) Compartmentalized cAMP signalling in regulated exocytic processes in non-neuronal cells. Cell Signal 20:590–601CrossRefPubMedGoogle Scholar
  115. Takeda S, Lin CT, Morgano PG, McIntyre SJ, Dousa TP (1991) High activity of low-Michaelis-Menten constant 3,5-cyclic adenosine monophosphate-phosphodiesterase isozymes in renal inner medulla of mice with hereditary nephrogenic diabetes insipidus. Endocrinology 129:287–294CrossRefPubMedGoogle Scholar
  116. Tamma G, Klussmann E, Maric K, Aktories K, Svelto M, Rosenthal W, Valenti G (2001) Rho inhibits cAMP-induced translocation of aquaporin-2 into the apical membrane of renal cells. Am J Physiol Ren Physiol 281:F1092–F1101CrossRefGoogle Scholar
  117. Tamma G, Klussmann E, Procino G, Svelto M, Rosenthal W, Valenti G (2003a) cAMP-induced AQP2 translocation is associated with RhoA inhibition through RhoA phosphorylation and interaction with RhoGDI. J Cell Sci 116:1519–1525CrossRefPubMedGoogle Scholar
  118. Tamma G, Wiesner B, Furkert J, Hahm D, Oksche A, Schaefer M, Valenti G, Rosenthal W, Klussmann E (2003b) The prostaglandin E2 analogue sulprostone antagonizes vasopressin-induced antidiuresis through activation of Rho. J Cell Sci 116:3285–3294CrossRefPubMedGoogle Scholar
  119. Taylor SS, Buechler JA, Yonemoto W (1990) cAMP-dependent protein kinase: framework for a diverse family of regulatory enzymes. Annu Rev Biochem 59:971–1005CrossRefPubMedGoogle Scholar
  120. Taylor SS, Ilouz R, Zhang P, Kornev AP (2012) Assembly of allosteric macromolecular switches: lessons from PKA. Nat Rev Mol Cell Biol 13:646–658CrossRefPubMedPubMedCentralGoogle Scholar
  121. Thajudeen B, Salahudeen AK (2016) Role of tolvaptan in the management of hyponatremia in patients with lung and other cancers: current data and future perspectives. Cancer Manag Res 8:105–114CrossRefPubMedPubMedCentralGoogle Scholar
  122. Torheim EA, Jarnæss E, Lygren B, Taskén K (2009) Design of proteolytically stable RI-anchoring disruptor peptidomimetics for in vivo studies of anchored type I protein kinase A-mediated signalling. Biochem J 424:69–78CrossRefPubMedGoogle Scholar
  123. Torres VE (2015) Vasopressin receptor antagonists, heart failure, and polycystic kidney disease. Annu Rev Med 66:195–210CrossRefPubMedGoogle Scholar
  124. Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Grantham JJ, Higashihara E, Perrone RD, Krasa HB, Ouyang J, Czerwiec FS (2012) Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med 367:2407–2418CrossRefPubMedPubMedCentralGoogle Scholar
  125. Trimpert C, Wesche D, de Groot T, Pimentel Rodriguez MM, Wong V, van den Berg DTM, Cheval L, Ariza CA, Doucet A, Stagljar I, Deen PMT (2017) NDFIP allows NEDD4/NEDD4L-induced AQP2 ubiquitination and degradation. PLoS One 12:e0183774CrossRefPubMedPubMedCentralGoogle Scholar
  126. Trotter KW, Fraser ID, Scott GK, Stutts MJ, Scott JD, Milgram SL (1999) Alternative splicing regulates the subcellular localization of A-kinase anchoring protein 18 isoforms. J Cell Biol 147:1481–1492CrossRefPubMedPubMedCentralGoogle Scholar
  127. Vukićević> T, Schulz M, Faust D, Klussmann E (2016) The trafficking of the water channel aquaporin-2 in renal principal cells—a potential target for pharmacological intervention in cardiovascular diseases. Front Pharmacol 7:23PubMedPubMedCentralGoogle Scholar
  128. Vukićević T, Hinze C, Baltzer S, Himmerkus N, Quintanova C, Zuhlke K, Compton F, Ahlborn R, Dema A, Eichhorst J, Wiesner B, Bleich M, Schmidt-Ott KM, Klussmann E (2019) Fluconazole increases osmotic water transport in renal collecting duct through effects on aquaporin-2 trafficking. J Am Soc Nephrol 30:795–810CrossRefPubMedGoogle Scholar
  129. Wahl-Schott C, Fenske S, Biel M (2014) HCN channels: new roles in sinoatrial node function. Curr Opin Pharmacol 15:83–90CrossRefPubMedGoogle Scholar
  130. Walker-Gray R, Stengel F, Gold MG (2017) Mechanisms for restraining cAMP-dependent protein kinase revealed by subunit quantitation and cross-linking approaches. Proc Natl Acad Sci U S A 114:10414–10419CrossRefPubMedPubMedCentralGoogle Scholar
  131. Wang Y, Ho TG, Bertinetti D, Neddermann M, Franz E, Mo GC, Schendowich LP, Sukhu A, Spelts RC, Zhang J, Herberg FW, Kennedy EJ (2014) Isoform-selective disruption of AKAP-localized PKA using hydrocarbon stapled peptides. ACS Chem Biol 9:635–642CrossRefPubMedPubMedCentralGoogle Scholar
  132. Wassermann AM, Kutchukian PS, Lounkine E, Luethi T, Hamon J, Bocker MT, Malik HA, Cowan-Jacob SW, Glick M (2013) Efficient search of chemical space: navigating from fragments to structurally diverse chemotypes. J Med Chem 56:8879–8891CrossRefPubMedGoogle Scholar
  133. Wells JA, McClendon CL (2007) Reaching for high-hanging fruit in drug discovery at protein-protein interfaces. Nature 450:1001–1009CrossRefGoogle Scholar
  134. Whiting JL, Ogier L, Forbush KA, Bucko P, Gopalan J, Seternes OM, Langeberg LK, Scott JD (2016) AKAP220 manages apical actin networks that coordinate aquaporin-2 location and renal water reabsorption. Proc Natl Acad Sci U S A 113:E4328–E4337CrossRefPubMedPubMedCentralGoogle Scholar
  135. Wiggins SV, Steegborn C, Levin LR, Buck J (2018) Pharmacological modulation of the CO2/HCO3(-)/pH-, calcium-, and ATP-sensing soluble adenylyl cyclase. Pharmacol TherGoogle Scholar
  136. Wilde F, Link A (2013) Advances in the design of a multipurpose fragment screening library. Expert Opin Drug Discovery 8:597–606CrossRefGoogle Scholar
  137. Wu Q, Moeller HB, Stevens DA, Sanchez-Hodge R, Childers G, Kortenoeven MLA, Cheng L, Rosenbaek LL, Rubel C, Patterson C, Pisitkun T, Schisler JC, Fenton RA (2018) CHIP regulates aquaporin-2 quality control and body water homeostasis. J Am Soc Nephrol 29:936–948PubMedGoogle Scholar
  138. Yandrapalli S, Jolly G, Biswas M, Rochlani Y, Harikrishnan P, Aronow WS, Lanier GM (2018) Newer hormonal pharmacotherapies for heart failure. Expert Rev Endocrinol Metab 13:35–49CrossRefPubMedGoogle Scholar
  139. Yang S, Fletcher WH, Johnson DA (1995) Regulation of cAMP-dependent protein kinase: enzyme activation without dissociation. Biochemistry 34:6267–6271CrossRefPubMedGoogle Scholar
  140. Yu X, Li F, Klussmann E, Stallone JN, Han G (2014) G protein-coupled estrogen receptor 1 mediates relaxation of coronary arteries via cAMP/PKA-dependent activation of MLCP. Am J Phys Endocrinol Metab 307:E398–E407CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Max Delbrück Center for Molecular Medicine Berlin (MDC), Helmholtz AssociationBerlinGermany
  2. 2.DZHK (German Centre for Cardiovascular Research), partner site BerlinBerlinGermany
  3. 3.Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health and Vegetative PhysiologyBerlinGermany

Personalised recommendations